Clinical characteristics, genomic profiling and outcomes of single system multifocal Langerhans cell histiocytosis in adults with bone involvement

Dear Editor, Langerhans cell histiocytosis (LCH) is a rare, heterogeneous histiocytic disease derived from the misguided clonal expansion of CD1a-positive and CD207-positive myeloid precursors cells [1]. LCH can affect individuals of all ages; however, it is more commonly in children [2]. The clinical presentation can manifest as a benign unifocal single-system (SS-s) disease, a single system multifocal (SS-m) disease, or a multisystem (MS) disease with life-threatening organ failure [3]. SS-m disease is de ﬁ ned as having more than one lesion involved in any single organ [3]. The bone is the most commonly involved organ presented in approximately 80% of LCH patients [4]. Recurrent BRAF V600E mutations were ﬁ rst identi ﬁ ed in 57% of LCH samples in 2010 [5]. Subsequently, other MAPK pathway mutations have also been discovered [6, 7]. It has been reported that BRAF V600E mutation occurred more frequently in pediatric patients than in adults [5]. However, no previous study has reported on the genetic mutations related to adult LCH with SS-m. Previous studies found that pediatric patients with central nerve system (CNS)-risk lesions involvement, which were de ﬁ ned as involving the craniofacial bone, orbital, ear, and oral structures, had a poor prognosis [8, 9]. Otherwise, the association between the outcome of LCH in adults with SS-m and CNS-risk lesions involvement has never been described. To clarify these questions, we retrospectively studied 43 adult LCH ( ≥ 18 years) with SS-m at Peking Union Medical College Hospital between January 2001 and May 2023. The diagnosis of LCH was based on histological ﬁ ndings in accordance with the World


Dear Editor,
Langerhans cell histiocytosis (LCH) is a rare, heterogeneous histiocytic disease derived from the misguided clonal expansion of CD1a-positive and CD207-positive myeloid precursors cells [1].LCH can affect individuals of all ages; however, it is more commonly in children [2].The clinical presentation can manifest as a benign unifocal single-system (SS-s) disease, a single system multifocal (SS-m) disease, or a multisystem (MS) disease with life-threatening organ failure [3].SS-m disease is defined as having more than one lesion involved in any single organ [3].The bone is the most commonly involved organ presented in approximately 80% of LCH patients [4].Recurrent BRAF V600E mutations were first identified in 57% of LCH samples in 2010 [5].Subsequently, other MAPK pathway mutations have also been discovered [6,7].It has been reported that BRAF V600E mutation occurred more frequently in pediatric patients than in adults [5].However, no previous study has reported on the genetic mutations related to adult LCH with SS-m.Previous studies found that pediatric patients with central nerve system (CNS)-risk lesions involvement, which were defined as involving the craniofacial bone, orbital, ear, and oral structures, had a poor prognosis [8,9].Otherwise, the association between the outcome of LCH in adults with SS-m and CNS-risk lesions involvement has never been described.
To clarify these questions, we retrospectively studied 43 adult LCH (≥18 years) with SS-m at Peking Union Medical College Hospital between January 2001 and May 2023.The diagnosis of LCH was based on histological findings in accordance with the World Health Organization classification of hematopoietic neoplasms [10].Patients with available tissues from the biopsy lesions underwent nextgeneration sequencing (NGS) of 183 genes to detected the presence of MAPK pathway mutations according to a previous described protocol (Table S1) [11].The initial therapies included local therapy (radiation or surgery) or systemic therapies: cytarabine-based therapies [12]; vindesine and prednisone-based (VP-based) regimens [13]; and BRAF inhibitors.Overall survival (OS) was calculated from the diagnosis to the date of death or last follow-up.Progression-free survival (PFS) was defined as the diagnosis to the occurrence of disease progression, relapse, death from any cause or last follow-up.The last follow-up date was May 20, 2023.The study was performed in accordance with Helsinki's declaration.
The initial treatments are shown in Fig. 2A.Seven patients (16.3%) did not receive treatments.Local therapy was initiated in six patients (14.0%), including complete surgical resection (mandible and maxilla) in one patient, and surgery and postoperative radiation in five patients.Of the five patients who received postoperative radiation, four received postoperative radiation for all bone lesions, while one (mandible and ribs involvement) only received postoperative radiation for the mandible lesions.A total of 30 patients received first-line systemic treatment: 18 received cytarabine monotherapy, six received MA, four received VP-based regimens, and two who had CNS-risk lesions received BRAF inhibitors.After a median duration of 43 months follow-up (range, 1-218 months), one was lost to follow-up and one died from disease progression.The 3-year OS and PFS rates were 97.4% and 75.4%, respectively (Fig. 2B).Thirteen patients showed disease reactivation.All patients who received local treatment experienced disease reactivation, including three at original bone lesions, one at both original (right mandible and left pelvis) and new (right pelvis) bone lesions, and two who progressed to MS LCH.Both patients treated with BRAF inhibitors remained stable until the last follow-up.Univariate analysis showed that first-line systemic therapy compared to local therapy (36.3 months vs. 28.0months, P = 0.013) and non-CNS-risk lesions involvement compared to CNS-risk lesions involvement (36.0 months vs. 23.0months, P = 0.016) indicated better PFS (Fig. 2C, D).In our result, we found that all adult patients with SS-m had bone involvement, and the ribs were the most common.Interestingly, we found SS-m LCH had a significantly higher frequency of CNS-risk lesions involvement than SS-s LCH.The discovery of MAPK pathway mutations has led to a better understanding of the pathophysiology of LCH.In the present cohort, the proportion of MAP2K1 mutations and BRAF deletions were lower than that in our whole cohort [14] and previous studies [6], whereas the percentage of BRAF V600E mutations was similar to that of the whole cohort.The overall percentage of MAPK pathway mutations in adult LCH with SS-m was lower than that of our previous study [11,14].These considerable disparities may have come from crushed bone samples and interference with mutations from decalcification [3].In addition, in our previous study, we found that BRAF deletion was the second most common MAPK pathway alternation in adult LCH, and that it strongly correlated with MS LCH in adults [11,14].Nevertheless, out of the 11 patients with BRAF mutations of SS-m LCH, only one harbored BRAF deletion.This supported that BRAF deletion is unusual in SS LCH.
The standard first-line treatment for LCH in adults remains undefined, and the treatment depends on symptoms and organ involvement [3,15].In this cohort, 69.8% received first-line systemic treatment, and had a better PFS than patients who received local therapy.It also was worth mentioning that both patients who received BRAF inhibitors have not reactivated until the last follow-up, but a long-term follow-up was necessary to monitor the future effect and progression.We also proved that non-CNS-risk lesions involvement strongly correlated with better PFS.
In conclusion, we found that bone was the most commonly affected system in adult LCH with SS-m.BRAF V600E mutation was the most common mutation among LCH in adults with SS-m, while the percentage of MAP2K1 mutations and BRAF deletion was low.First-line systemic treatment and non-CNS-risk lesions involvement predicted better PFS.

Fig. 1
Fig. 1 Mutational profiles of LCH in adults with single-system multifocal disease.Next-generation sequencing of lesion tissues of LCH in adults with single-system multifocal disease (SS-m).

Fig. 2
Fig. 2 Treatment and outcomes of adult patients with SS-m.A The initial treatment and response of LCH in adult with SS-m; B Overall survival (OS) and progression-free survival (PFS) of adult patients with SS-m; PFS according to first-line treatment (C), and CNS-risk lesions involvement at baseline (D).